Unknown

Dataset Information

0

DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclax.


ABSTRACT: Rationale: microRNAs (miRNAs) are frequently deregulated and play important roles in the pathogenesis and progression of acute myeloid leukemia (AML). miR-182 functions as an onco-miRNA or tumor suppressor miRNA in the context of different cancers. However, whether miR-182 affects the self-renewal of leukemia stem cells (LSCs) and normal hematopoietic stem progenitor cells (HSPCs) is unknown. Methods: Bisulfite sequencing was used to analyze the methylation status at pri-miR-182 promoter. Lineage-negative HSPCs were isolated from miR-182 knockout (182KO) and wild-type (182WT) mice to construct MLL-AF9-transformed AML model. The effects of miR-182 depletion on the overall survival and function of LSC were analyzed in this mouse model in vivo. Results: miR-182-5p (miR-182) expression was lower in AML blasts than normal controls (NCs) with hypermethylation observed at putative pri-miR-182 promoter in AML blasts but unmethylation in NCs. Overexpression of miR-182 inhibited proliferation, reduced colony formation, and induced apoptosis in leukemic cells. In addition, depletion of miR-182 accelerated the development and shortened the overall survival (OS) in MLL-AF9-transformed murine AML through increasing LSC frequency and self-renewal ability. Consistently, overexpression of miR-182 attenuated AML development and extended the OS in the murine AML model. Most importantly, miR-182 was likely dispensable for normal hematopoiesis. Mechanistically, we identified BCL2 and HOXA9 as two key targets of miR-182 in this context. Most importantly, AML patients with miR-182 unmethylation had high expression of miR-182 followed by low protein expression of BCL2 and resistance to BCL2 inhibitor venetoclax (Ven) in vitro. Conclusions: Our results suggest that miR-182 is a potential therapeutic target for AML patients through attenuating the self-renewal of LSC but not HSPC. miR-182 promoter methylation could determine the sensitivity of Ven treatment and provide a potential biomarker for it.

SUBMITTER: Ye S 

PROVIDER: S-EPMC9800726 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

altmetric image

Publications

DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclax.

Ye Sisi S   Xiong Fang F   He Xiaofei X   Yuan Yigang Y   Li Danyang D   Ye Daijiao D   Shi Liuzhi L   Lin Zihan Z   Zhao Min M   Feng Shuya S   Zhou Bin B   Weng Huachun H   Hong Lili L   Ye Haige H   Gao Shenmeng S  

Theranostics 20230101 1


<b>Rationale:</b> microRNAs (miRNAs) are frequently deregulated and play important roles in the pathogenesis and progression of acute myeloid leukemia (AML). miR-182 functions as an onco-miRNA or tumor suppressor miRNA in the context of different cancers. However, whether miR-182 affects the self-renewal of leukemia stem cells (LSCs) and normal hematopoietic stem progenitor cells (HSPCs) is unknown. <b>Methods:</b> Bisulfite sequencing was used to analyze the methylation status at pri-miR-182 pr  ...[more]

Similar Datasets

| S-EPMC10964616 | biostudies-literature
2025-03-01 | GSE260974 | GEO
| S-EPMC7107002 | biostudies-literature
| S-EPMC10603903 | biostudies-literature
| S-EPMC6717583 | biostudies-literature
| S-EPMC4767347 | biostudies-literature
| S-EPMC7049339 | biostudies-literature
| S-EPMC8088697 | biostudies-literature
| S-EPMC10236156 | biostudies-literature